Such evaluation now appears to be of paramount importance, as the selective aromatase inhibitors (eg anastrozole) have recently been shown to be the preferred first-line endocrine therapy to tamoxifen in postmenopausal women with advanced breast cancer. The gene discussed is CYP19A1; the disease is breast cancer.